Beyond GSBR-1290, Structure is developing next generation combination GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefits.

Source: https://forextv.com/top-news/structure-therapeutics-announces-positive-results-from-phase-1b-clinical-study-of-oral-glp-1-receptor-agonist-gsbr-1290-and-provides-program-update/

Beyond GSBR-1290, Structure is developing next generation combination GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefits.

Source: https://forextv.com/top-news/structure-therapeutics-announces-positive-results-from-phase-1b-clinical-study-of-oral-glp-1-receptor-agonist-gsbr-1290-and-provides-program-update/

Drugs based on melanocortin agonists have been approved by the FDA for treating several conditions, including inflammatory/autoimmune diseases, rare forms of genetic obesity and female sexual dysfunction.

Source: https://www.prnewswire.com/news-releases/pre-clinical-data-of-palatins-melanocortin-agonist-demonstrating-therapeutic-effects-in-diabetic-retinopathy-and-uveitis-published-in-the-international-journal-of-molecular-sciences-301799835.html

The GLP-1 receptor agonists also work by slowing down digestion of food and increasing the feeling of being full after eating.

Source: https://indianexpress.com/article/health-wellness/pfizer-halts-trial-for-twice-a-day-weight-loss-drug-what-triggered-this-and-how-does-this-affect-the-user-9051544/

These drugs belong to a class of medications called glucagon-like peptide-1 (GLP-1) receptor agonists, which mimic the action of a naturally occurring hormone in the body that regulates blood sugar levels and appetite.

Source: https://www.huffingtonpost.co.uk/entry/im-a-psychologist-heres-why-ozempics-glorification-has-left-me-frustrated-and-fearful_uk_6465e127e4b0355739341f1e